Clinical Trials
40
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.
- Conditions
- Epilepsy
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- LivaNova
- Target Recruit Count
- 15
- Registration Number
- NCT05975931
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
- Conditions
- OSAApnea, ObstructiveApneaHypopnea, SleepObstructive Sleep ApneaApnea, Obstructive SleepApnea+Hypopnea
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- LivaNova
- Target Recruit Count
- 150
- Registration Number
- NCT04950894
- Locations
- 🇺🇸
University of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸Banner Health, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.
- Conditions
- Epilepsy
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- LivaNova
- Target Recruit Count
- 97
- Registration Number
- NCT04779814
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Bristol Royal Hospital For Children, Bristol, United Kingdom
🇬🇧The Walton Centre, Liverpool, United Kingdom
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
- Conditions
- Treatment Resistant Depression
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- LivaNova
- Target Recruit Count
- 138
- Registration Number
- NCT04753385
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸ATP Clinical Research, Inc., Costa Mesa, California, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)
- Conditions
- Epilepsy, Tonic-Clonic
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- LivaNova
- Registration Number
- NCT04282681
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
LivaNova's CORE-VNS Study Demonstrates Sustained Seizure Reduction in Drug-Resistant Epilepsy Patients
LivaNova's comprehensive CORE-VNS study of over 800 patients worldwide demonstrates sustained effectiveness of VNS Therapy for drug-resistant epilepsy over 36 months.
Vagus Nerve Stimulation Shows Promise for Treatment-Resistant Depression
A large-scale clinical trial reveals that vagus nerve stimulation (VNS) can significantly improve depressive symptoms, quality of life, and daily functioning in individuals with severe, treatment-resistant depression.
Livanova's Aura6000 Meets Endpoints in Sleep Apnea Implant Trial
Livanova's aura6000 hypoglossal nerve stimulator met primary safety and efficacy endpoints in a randomized trial for obstructive sleep apnea (OSA).
LivaNova's Aura6000 System Shows Promise in Obstructive Sleep Apnea Trial
LivaNova's OSPREY trial met primary safety and efficacy endpoints for the aura6000 system, an implantable device for moderate to severe obstructive sleep apnea.
Device-Based Therapies Reshape Chronic Heart Failure Treatment Landscape
• Device-based therapies are increasingly integral in managing chronic heart failure, offering solutions for structural and neurohormonal abnormalities. • The FDA's Breakthrough Device Program expedites access to innovative heart failure devices, fostering development and evaluation of these therapies. • Recent approvals and novel therapies target structural or neurohormonal issues, complementing pharmacological treatments and filling gaps in unmet needs, such as HFpEF. • Approved devices include MitraClip for mitral regurgitation, Barostim neo for autonomic modulation, and the remedē System for central sleep apnea.